Combination with Methotrexate and Cyclophosphamide Attenuated Maturation of Dendritic Cells: Inducing Treg Skewing and Th17 Suppression In Vivo

Table 5

BMDC surface antigen’s expression of MTX combined with CTX group.

Week	𝑛	BMDC surface antigen’s expression (𝑋±𝑆, %)
		CD11c	CD40	CD80	CD86	MHC-II
0	6	87.85±4.51	69.72±4.70	89.78±3.67	79.37±3.60	84.32±2.81
3	5	86.10±2.85	67.70±3.97	87.40±3.29	77.90±3.83	82.44±4.53
6	5	84.20±3.18	64.20±3.30^∗	84.00±2.73^∗	73.50±4.74^∗	77.56±4.85^∗#
9	6	83.32±1.81^∗	59.47±2.27^∗#△	79.17±1.94^∗#△	68.17±2.07^∗#△	71.87±2.20^∗#△

Values are expressed as mean ± standard deviation; the differences of BMDC surface molecules, CD40, at different time were determined by Kruskal-Wallis H test. The DC surface antigen’s expression was significantly decreased on 9th week.
*Compared with 0 week, 𝑃<0.05; ^#compared with 3rd week, 𝑃<0.05; ^△compared with 6th week, 𝑃<0.05.